M. Makowsky

Tremelimumab plus Durvalumab in Unresectable Hepatocellular Carcinoma.

M. Kudo, P. Galle, J. Furuse, 2022, NEJM evidence.

Durvalumab plus Gemcitabine and Cisplatin in Advanced Biliary Tract Cancer.

J. W. Kim, M. Ikeda, Li‐Tzong Chen, 2022, NEJM evidence.

Phase I/II study of durvalumab and tremelimumab in patients with unresectable hepatocellular carcinoma (HCC): Phase I safety and efficacy analyses.

M. Rebelatto, M. Borad, G. Abou-Alfa, 2017 .

Safety, Efficacy, and Pharmacodynamics of Tremelimumab Plus Durvalumab for Patients With Unresectable Hepatocellular Carcinoma: Randomized Expansion of a Phase I/II Study

A. Gasbarrini, M. Kudo, J. Bruix, 2021, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

67O Outcomes in the Asian subgroup of the phase III HIMALAYA study of tremelimumab (T) plus durvalumab (D) in unresectable hepatocellular carcinoma (uHCC)

P. Sunpaweravong, J. Furuse, G. Abou-Alfa, 2022, Annals of Oncology.

714P Impact of viral aetiology in the phase III HIMALAYA study of tremelimumab (T) plus durvalumab (D) in unresectable hepatocellular carcinoma (uHCC)

P. Sunpaweravong, J. Furuse, G. Abou-Alfa, 2022, Annals of Oncology.

O-5 Outcomes by baseline liver function in patients with unresectable hepatocellular carcinoma treated with tremelimumab and durvalumab in the phase 3 HIMALAYA study

J. Furuse, G. Abou-Alfa, G. Masi, 2022, Annals of Oncology.

Population Pharmacokinetics and Exposure–Response Analysis of Tremelimumab 300 mg Single Dose Combined with Durvalumab 1500 mg Q4W (STRIDE) in Patients with Unresectable Hepatocellular Carcinoma

A. Phipps, D. Zhou, Song Ren, 2023, Journal of clinical pharmacology.

(2)H,(15)N-substituted nitroxides as sensitive probes for electron paramagnetic resonance imaging.

J. Kao, G. Rosen, S. Muralidharan, 2010, The Journal of organic chemistry.

Regional subgroup analysis of the phase 3 TOPAZ-1 study of durvalumab (D) plus gemcitabine and cisplatin (GC) in advanced biliary tract cancer (BTC).

J. W. Kim, Li‐Tzong Chen, A. Vogel, 2022, Journal of Clinical Oncology.

Four-year overall survival update from the phase III HIMALAYA study of tremelimumab plus durvalumab in unresectable hepatocellular carcinoma.

T. Crocenzi, Tae-You Kim, Y. Hotko, 2024, Annals of oncology : official journal of the European Society for Medical Oncology.